Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
Joseph PidalaKelly WaltonHany ElmariahJongphil KimAsmita MishraNelli BejanyanTaiga NishihoriFarhad KhimaniLia PerezRawan G FaramandMarco L DavilaMichael L NiederElizabeth M SagatysShernan G HoltanNicholas J LawrenceHarshani R LawrenceBruce R BlazarClaudio AnasettiSaid M SebtiBrian C BettsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
We demonstrate that PAC/SIR/TAC is safe and preliminarily limits acute GVHD, preserves donor CMV immunity, and permits timely engraftment. The efficacy of PAC/SIR/TAC will be tested in our ongoing phase II GVHD prevention trial.
Keyphrases
- phase ii
- clinical trial
- open label
- low dose
- allogeneic hematopoietic stem cell transplantation
- phase iii
- stem cell transplantation
- placebo controlled
- double blind
- liver failure
- hematopoietic stem cell
- study protocol
- high dose
- bone marrow
- respiratory failure
- acute myeloid leukemia
- acute lymphoblastic leukemia
- drug induced
- aortic dissection
- cell therapy
- mesenchymal stem cells
- hepatitis b virus